Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""carvedilol"" wg kryterium: Temat


Tytuł :
Determination and Comparison of the Solubility, Oil-Water Partition Coefficient, Intestinal Absorption, and Biliary Excretion of Carvedilol Enantiomers.
Autorzy :
Zhang Q; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, No. 1838, North Guangzhou Avenue, Guangzhou, China.; Institute of Materia Medica, Hangzhou Medical College, Hangzhou, China.
Wang X; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, No. 1838, North Guangzhou Avenue, Guangzhou, China.
Xue H; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, No. 1838, North Guangzhou Avenue, Guangzhou, China.
Huang B; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, No. 1838, North Guangzhou Avenue, Guangzhou, China.
Lin Z; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, No. 1838, North Guangzhou Avenue, Guangzhou, China.
Cai Z; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, No. 1838, North Guangzhou Avenue, Guangzhou, China. .
Pokaż więcej
Źródło :
AAPS PharmSciTech [AAPS PharmSciTech] 2021 Jan 10; Vol. 22 (1), pp. 43. Date of Electronic Publication: 2021 Jan 10.
Typ publikacji :
Journal Article
MeSH Terms :
Intestinal Absorption*
Bile/*metabolism
Carvedilol/*chemistry
Animals ; Carvedilol/pharmacokinetics ; Male ; Rats ; Rats, Sprague-Dawley ; Solubility ; Stereoisomerism
Czasopismo naukowe
Tytuł :
Effect of carvedilol on arteriovenous graft primary patency.
Autorzy :
Tseng YH; Division of Thoracic and Cardiovascular Surgery, Chia Yi Chang Gung Memorial Hospital, Chia-Yi and Chang Gung University, College of Medicine, Taoyuan.
Liu CY; Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital, Chiayi Branch.
Lee CP; Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital, Chiayi Branch.
Lin MH; Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital, Chiayi Branch.
Yang YH; Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital, Chiayi Branch.; Department for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Chiayi.; School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Pokaż więcej
Źródło :
Vascular [Vascular] 2020 Dec; Vol. 28 (6), pp. 765-774. Date of Electronic Publication: 2020 May 14.
Typ publikacji :
Journal Article
MeSH Terms :
Arteriovenous Shunt, Surgical*/adverse effects
Renal Dialysis*
Adrenergic alpha-1 Receptor Antagonists/*administration & dosage
Carvedilol/*administration & dosage
Graft Occlusion, Vascular/*prevention & control
Kidney Failure, Chronic/*therapy
Vascular Patency/*drug effects
Adrenergic alpha-1 Receptor Antagonists/adverse effects ; Aged ; Angioplasty ; Carvedilol/adverse effects ; Databases, Factual ; Female ; Graft Occlusion, Vascular/diagnostic imaging ; Graft Occlusion, Vascular/etiology ; Graft Occlusion, Vascular/physiopathology ; Humans ; Kidney Failure, Chronic/diagnosis ; Male ; Middle Aged ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Taiwan ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
β-arrestin 2 as an activator of cGAS-STING signaling and target of viral immune evasion.
Autorzy :
Zhang Y; Department of Immunology, School of Basic Medical Sciences & Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, 200032, China.
Li M; Department of Immunology, School of Basic Medical Sciences & Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, 200032, China.
Li L; Department of Immunology, School of Basic Medical Sciences & Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, 200032, China.
Qian G; Department of Immunology, School of Basic Medical Sciences & Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, 200032, China.
Wang Y; Department of Microbiology and Biochemical Pharmacy, National Engineering Research Centre of Immunological Products, College of Pharmacy, Army Medical University, Chongqing, 400038, China.
Chen Z; Department of Immunology, School of Basic Medical Sciences & Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, 200032, China.
Liu J; Department of Immunology, School of Basic Medical Sciences & Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, 200032, China.
Fang C; Department of Vascular Surgery, Zhongshan Hospital Affiliated to Fudan University, Institute of Vascular Surgery, Fudan University, Shanghai, 200032, China.
Huang F; Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, China.
Guo D; Department of Vascular Surgery, Zhongshan Hospital Affiliated to Fudan University, Institute of Vascular Surgery, Fudan University, Shanghai, 200032, China.
Zou Q; Department of Microbiology and Biochemical Pharmacy, National Engineering Research Centre of Immunological Products, College of Pharmacy, Army Medical University, Chongqing, 400038, China.
Chu Y; Department of Immunology, School of Basic Medical Sciences & Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, 200032, China.
Yan D; Department of Immunology, School of Basic Medical Sciences & Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, 200032, China. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Nov 26; Vol. 11 (1), pp. 6000. Date of Electronic Publication: 2020 Nov 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carvedilol/*pharmacology
Immune Evasion/*immunology
Membrane Proteins/*metabolism
Nucleotidyltransferases/*metabolism
Virus Diseases/*immunology
beta-Arrestin 2/*metabolism
Animals ; Carvedilol/therapeutic use ; Disease Models, Animal ; Drug Repositioning ; HEK293 Cells ; Herpesvirus 1, Human/immunology ; Humans ; Immune Evasion/drug effects ; Interferon-beta/metabolism ; Macrophages, Peritoneal/immunology ; Macrophages, Peritoneal/metabolism ; Male ; Mice ; Primary Cell Culture ; Proteolysis/drug effects ; RAW 264.7 Cells ; RNA-Seq ; Sendai virus/immunology ; Signal Transduction/drug effects ; Signal Transduction/immunology ; Vesiculovirus/immunology ; Virus Diseases/drug therapy ; Virus Diseases/virology ; beta-Arrestin 2/agonists ; beta-Arrestin 2/genetics
Czasopismo naukowe
Tytuł :
Carvedilol safeguards against aspirin-induced gastric damage in rats.
Autorzy :
Ahmed I; Department of Pharmacology and Toxicology, Nizam Institute of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad, Telangana, India.
Elkablawy MA; Department of Pathology, Faculty of Medicine, Menoufia University, Menoufia, Egypt.
El-Agamy DS; Department of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Al-Madinah Al-Munawwarah, Saudi Arabia.; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Bazarbay AA; Department of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Al-Madinah Al-Munawwarah, Saudi Arabia.
Ahmed N; Department of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Al-Madinah Al-Munawwarah, Saudi Arabia.
Pokaż więcej
Źródło :
Human & experimental toxicology [Hum Exp Toxicol] 2020 Sep; Vol. 39 (9), pp. 1257-1267. Date of Electronic Publication: 2020 Apr 15.
Typ publikacji :
Journal Article
MeSH Terms :
Adrenergic beta-Antagonists/*administration & dosage
Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
Antioxidants/*administration & dosage
Aspirin/*adverse effects
Carvedilol/*administration & dosage
Stomach Ulcer/*chemically induced
Stomach Ulcer/*prevention & control
Adrenergic beta-Antagonists/pharmacology ; Animals ; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ; Antioxidants/pharmacology ; Aspirin/administration & dosage ; Carvedilol/pharmacology ; Cytokines/analysis ; Male ; Oxidative Stress/drug effects ; Rats ; Rats, Wistar
Czasopismo naukowe
Tytuł :
Hot melt-extrusion improves the properties of cyclodextrin-based poly(pseudo)rotaxanes for transdermal formulation.
Autorzy :
Marreto RN; Laboratory of Nanosystems and Drug Delivery Devices (NanoSYS), School of Pharmacy, Universidade Federal de Goiás (UFG), Rua 240, Setor Leste Universitário, 74605-170 Goiânia, GO, Brazil. Electronic address: .
Cardoso G; Laboratory of Nanosystems and Drug Delivery Devices (NanoSYS), School of Pharmacy, Universidade Federal de Goiás (UFG), Rua 240, Setor Leste Universitário, 74605-170 Goiânia, GO, Brazil.
Dos Santos Souza B; Laboratory of Nanosystems and Drug Delivery Devices (NanoSYS), School of Pharmacy, Universidade Federal de Goiás (UFG), Rua 240, Setor Leste Universitário, 74605-170 Goiânia, GO, Brazil.
Martin-Pastor M; Unidad de Resonancia Magnética Nuclear, RIAIDT, Edificio CACTUS, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Cunha-Filho M; Laboratory of Food, Drug and Cosmetics (LTMAC), School of Health Sciences, University of Brasilia, Brasília, DF, 70.910-900, Brazil.
Taveira SF; Laboratory of Nanosystems and Drug Delivery Devices (NanoSYS), School of Pharmacy, Universidade Federal de Goiás (UFG), Rua 240, Setor Leste Universitário, 74605-170 Goiânia, GO, Brazil.
Concheiro A; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma Group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
Alvarez-Lorenzo C; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma Group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain. Electronic address: .
Pokaż więcej
Źródło :
International journal of pharmaceutics [Int J Pharm] 2020 Aug 30; Vol. 586, pp. 119510. Date of Electronic Publication: 2020 Jun 09.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
2-Hydroxypropyl-beta-cyclodextrin/*chemistry
Carvedilol/*administration & dosage
Excipients/*chemistry
Rotaxanes/*chemistry
Administration, Cutaneous ; Adrenergic beta-Antagonists/administration & dosage ; Adrenergic beta-Antagonists/chemistry ; Carvedilol/chemistry ; Chemistry, Pharmaceutical ; Drug Liberation ; Gels ; Plasticizers/chemistry ; Polyethylene Glycols/chemistry ; Polymers/chemistry ; Rheology ; Viscosity ; alpha-Cyclodextrins/chemistry
Czasopismo naukowe
Tytuł :
Not the usual suspects: DRESS secondary to carvedilol.
Autorzy :
Jones L; Canterbury District Health Board, Christchurch.
Isenmen H; Canterbury District Health Board, Christchurch.
Pokaż więcej
Źródło :
The New Zealand medical journal [N Z Med J] 2020 Oct 09; Vol. 133 (1523), pp. 104-105. Date of Electronic Publication: 2020 Oct 09.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Drug Hypersensitivity Syndrome*
Cardiovascular Agents/*adverse effects
Carvedilol/*adverse effects
Aged ; Cardiovascular Agents/therapeutic use ; Carvedilol/therapeutic use ; Female ; Humans ; New Zealand ; Ventricular Dysfunction, Left/drug therapy
Czasopismo naukowe
Tytuł :
Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2.
Autorzy :
Skayem C; Université de Paris, Faculté de Médecine, Paris; Assistance Publique des Hôpitaux de Paris (APHP), Paris; Hôpital Henri Mondor, Créteil, France. Electronic address: .
Ayoub N; Holy Spirit University of Kaslik, Lebanon; Centre Hospitalier Notre Dame des Secours (CHUNDS), Byblos, Lebanon.
Pokaż więcej
Źródło :
The American journal of the medical sciences [Am J Med Sci] 2020 Sep; Vol. 360 (3), pp. 300. Date of Electronic Publication: 2020 May 28.
Typ publikacji :
Letter
MeSH Terms :
Betacoronavirus*
Severity of Illness Index*
Carvedilol/*therapeutic use
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Vasodilator Agents/*therapeutic use
Angiotensin-Converting Enzyme 2 ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; COVID-19 ; Carvedilol/pharmacology ; Coronavirus Infections/metabolism ; Disease Transmission, Infectious/prevention & control ; Humans ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/metabolism ; Pandemics ; Peptidyl-Dipeptidase A/metabolism ; Pneumonia, Viral/metabolism ; SARS-CoV-2 ; Vasodilator Agents/pharmacology
Opinia redakcyjna
Tytuł :
Binary polymeric amorphous carvedilol solid dispersions: In vitro and in vivo characterization.
Autorzy :
Krstić M; University of Belgrade - Faculty of Pharmacy, Department of Analytical Chemistry, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: .
Manić L; University of Belgrade - Faculty of Pharmacy, PhD student, Vojvode Stepe 450, 11221 Belgrade, Serbia.
Martić N; University of Novi Sad, Faculty of Medicine, Department of Pharmacology, Toxicology and Clinical Pharmacology, Hajduk Veljkova 3, 21000 Novi Sad, Serbia. Electronic address: .
Vasiljević D; University of Belgrade - Faculty of Pharmacy, Department of Pharmaceutical Technology and Cosmetology, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: .
Mračević SĐ; University of Belgrade - Faculty of Pharmacy, Department of Analytical Chemistry, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: .
Vukmirović S; University of Novi Sad, Faculty of Medicine, Department of Pharmacology, Toxicology and Clinical Pharmacology, Hajduk Veljkova 3, 21000 Novi Sad, Serbia. Electronic address: .
Rašković A; University of Novi Sad, Faculty of Medicine, Department of Pharmacology, Toxicology and Clinical Pharmacology, Hajduk Veljkova 3, 21000 Novi Sad, Serbia. Electronic address: .
Pokaż więcej
Źródło :
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2020 Jul 01; Vol. 150, pp. 105343. Date of Electronic Publication: 2020 May 04.
Typ publikacji :
Journal Article
MeSH Terms :
Antihypertensive Agents*/administration & dosage
Antihypertensive Agents*/blood
Antihypertensive Agents*/chemistry
Antihypertensive Agents*/pharmacokinetics
Carvedilol*/administration & dosage
Carvedilol*/blood
Carvedilol*/chemistry
Carvedilol*/pharmacokinetics
Drug Carriers*/administration & dosage
Drug Carriers*/chemistry
Drug Carriers*/pharmacokinetics
Excipients*/administration & dosage
Excipients*/chemistry
Excipients*/pharmacokinetics
Polymers*/administration & dosage
Polymers*/chemistry
Polymers*/pharmacokinetics
Animals ; Biological Availability ; Drug Liberation ; Kidney/drug effects ; Liver/drug effects ; Male ; Rats, Wistar
Czasopismo naukowe
Tytuł :
Long-term outcome of carvedilol therapy in Japanese patients with nonischemic heart failure.
Autorzy :
Nagara K; Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
Suzuki A; Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
Shiga T; Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan. .; Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan. .
Hagiwara N; Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
Pokaż więcej
Źródło :
Heart and vessels [Heart Vessels] 2020 Jul; Vol. 35 (7), pp. 957-966. Date of Electronic Publication: 2020 Jan 22.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Adrenergic beta-Antagonists/*administration & dosage
Carvedilol/*administration & dosage
Heart Failure/*drug therapy
Stroke Volume/*drug effects
Ventricular Function, Left/*drug effects
Adrenergic beta-Antagonists/adverse effects ; Adult ; Aged ; Carvedilol/adverse effects ; Female ; Heart Failure/diagnosis ; Heart Failure/mortality ; Heart Failure/physiopathology ; Heart Rate/drug effects ; Humans ; Japan ; Male ; Middle Aged ; Recovery of Function ; Retrospective Studies ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification.
Autorzy :
Wang Y; Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
He X; Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
Li C; Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
Ma Y; Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
Xue W; Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
Hu B; Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
Wang J; Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
Zhang T; Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
Zhang F; Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2020 May 01; Vol. 193, pp. 112235. Date of Electronic Publication: 2020 Mar 16.
Typ publikacji :
Journal Article
MeSH Terms :
Carvedilol/*pharmacology
Cytochrome P-450 CYP1B1/*antagonists & inhibitors
Enzyme Inhibitors/*pharmacology
A549 Cells ; Carvedilol/chemistry ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Cytochrome P-450 CYP1B1/chemistry ; Cytochrome P-450 CYP1B1/metabolism ; Density Functional Theory ; Dose-Response Relationship, Drug ; Drug Evaluation, Preclinical ; Drug Repositioning ; Drug Screening Assays, Antitumor ; Enzyme Inhibitors/chemistry ; Humans ; Models, Molecular ; Molecular Structure ; Structure-Activity Relationship ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Carvedilol and metoprolol are both able to preserve myocardial function in type 2 diabetes.
Autorzy :
Bussey CT; Department of Physiology-HeartOtago, Otago School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Babakr AA; Department of Physiology-HeartOtago, Otago School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Iremonger RR; Department of Physiology-HeartOtago, Otago School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
van Hout I; Department of Physiology-HeartOtago, Otago School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Wilkins GT; Department of Medicine-HeartOtago, Dunedin School of Medicine, Dunedin Hospital, Dunedin, New Zealand.
Lamberts RR; Department of Physiology-HeartOtago, Otago School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Erickson JR; Department of Physiology-HeartOtago, Otago School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Pokaż więcej
Źródło :
Physiological reports [Physiol Rep] 2020 Mar; Vol. 8 (5), pp. e14394.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adrenergic beta-1 Receptor Antagonists/*therapeutic use
Carvedilol/*therapeutic use
Diabetes Mellitus, Type 2/*drug therapy
Heart/*drug effects
Metoprolol/*therapeutic use
Aged ; Animals ; Carvedilol/administration & dosage ; Coronary Artery Bypass/methods ; Diabetes Mellitus, Type 2/physiopathology ; Disease Models, Animal ; Female ; Heart/physiopathology ; Humans ; Male ; Metoprolol/administration & dosage ; Middle Aged ; Rats, Zucker ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease.
Autorzy :
Hanauer Schaab E; Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Lanchote VL; Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Balthazar Nardotto GH; Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Marques Pereira MP; Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Dantas M; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Paiva CE; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Barbosa Coelho E; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Pokaż więcej
Źródło :
Journal of clinical pharmacology [J Clin Pharmacol] 2020 Jan; Vol. 60 (1), pp. 75-85. Date of Electronic Publication: 2019 Jul 28.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antihypertensive Agents/*pharmacokinetics
Antihypertensive Agents/*therapeutic use
Carvedilol/*pharmacokinetics
Carvedilol/*therapeutic use
Dihydropyridines/*pharmacokinetics
Dihydropyridines/*therapeutic use
Renal Insufficiency, Chronic/*metabolism
Administration, Oral ; Adult ; Antihypertensive Agents/administration & dosage ; Antihypertensive Agents/chemistry ; Carvedilol/administration & dosage ; Carvedilol/chemistry ; Case-Control Studies ; Cross-Over Studies ; Cytochrome P-450 Enzyme System/metabolism ; Dihydropyridines/administration & dosage ; Drug Interactions ; Female ; Glomerular Filtration Rate ; Heart Rate/drug effects ; Humans ; Hypertension/complications ; Hypertension/drug therapy ; Male ; Middle Aged ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/drug therapy ; Stereoisomerism
Czasopismo naukowe
Tytuł :
Editorial: Beta blockers and cirrhosis-more than just portal hypertension?
Autorzy :
Ttl Tjwa E; Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Mar; Vol. 53 (5), pp. 644-645.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Hypertension, Portal*
Adrenergic beta-Antagonists/adverse effects ; Carvedilol ; Follow-Up Studies ; Humans ; Liver Cirrhosis
Opinia redakcyjna
Tytuł :
Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study.
Autorzy :
McDowell HR; Department of Hepatology, Royal Infirmary of Edinburgh, Edinburgh, UK.
Chuah CS; Department of Hepatology, Royal Infirmary of Edinburgh, Edinburgh, UK.
Tripathi D; Liver Unit, Queen Elizabeth Hospital, Birmingham, UK.
Stanley AJ; Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK.
Forrest EH; Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK.
Hayes PC; Department of Hepatology, Royal Infirmary of Edinburgh, Edinburgh, UK.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Feb; Vol. 53 (4), pp. 531-539. Date of Electronic Publication: 2020 Dec 09.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Esophageal and Gastric Varices*/drug therapy
Adrenergic beta-Antagonists/therapeutic use ; Carvedilol/therapeutic use ; Follow-Up Studies ; Gastrointestinal Hemorrhage/etiology ; Gastrointestinal Hemorrhage/prevention & control ; Humans ; Liver Cirrhosis/complications ; Liver Cirrhosis/drug therapy ; Prospective Studies ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Effects of β 2 -receptor stimulation by indacaterol in chronic heart failure treated with selective or non-selective β-blockers: a randomized trial.
Autorzy :
Contini M; Centro Cardiologico Monzino, IRCCS, Milano, Italy.
Spadafora E; Centro Cardiologico Monzino, IRCCS, Milano, Italy.
Barbieri S; Centro Cardiologico Monzino, IRCCS, Milano, Italy.
Gugliandolo P; Centro Cardiologico Monzino, IRCCS, Milano, Italy.
Salvioni E; Centro Cardiologico Monzino, IRCCS, Milano, Italy.
Magini A; Centro Cardiologico Monzino, IRCCS, Milano, Italy.
Apostolo A; Centro Cardiologico Monzino, IRCCS, Milano, Italy.
Palermo P; Centro Cardiologico Monzino, IRCCS, Milano, Italy.
Alimento M; Centro Cardiologico Monzino, IRCCS, Milano, Italy.
Agostoni P; Centro Cardiologico Monzino, IRCCS, Milano, Italy. .; Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milano, Milano, Italy. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Apr 28; Vol. 10 (1), pp. 7101. Date of Electronic Publication: 2020 Apr 28.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adrenergic beta-2 Receptor Agonists/*administration & dosage
Adrenergic beta-Antagonists/*administration & dosage
Bisoprolol/*administration & dosage
Carvedilol/*administration & dosage
Heart Failure/*drug therapy
Indans/*administration & dosage
Quinolones/*administration & dosage
Adrenergic beta-2 Receptor Agonists/adverse effects ; Adrenergic beta-Antagonists/adverse effects ; Aged ; Bisoprolol/adverse effects ; Carvedilol/adverse effects ; Cross-Over Studies ; Double-Blind Method ; Female ; Heart Failure/pathology ; Heart Failure/physiopathology ; Humans ; Indans/adverse effects ; Male ; Middle Aged ; Prospective Studies ; Quinolones/adverse effects ; Receptors, Adrenergic, beta-2/metabolism
Czasopismo naukowe
Tytuł :
Proteomics Analysis of Trastuzumab Toxicity in the H9c2 Cardiomyoblast Cell Line and its Inhibition by Carvedilol.
Autorzy :
Beiranvand E; Protein Chemistry and Proteomics Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Torkashvand F; Protein Chemistry and Proteomics Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Ostad SN; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Mirzaie M; Department of Molecular Sciences, Macquarie University, Sydney, NSW, Australia; Australian Proteome Analysis Facility, Macquarie University, Sydney, NSW, Australia
Ardakani EM; Protein Chemistry and Proteomics Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Zandi F; Protein Chemistry and Proteomics Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Sardari S; Protein Chemistry and Proteomics Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Salekdeh GH; Department of Molecular Systems Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
Shokrgozar MA; National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran
Vaziri B; Protein Chemistry and Proteomics Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Pokaż więcej
Źródło :
Current pharmaceutical biotechnology [Curr Pharm Biotechnol] 2020; Vol. 21 (13), pp. 1377-1385.
Typ publikacji :
Journal Article
MeSH Terms :
Adrenergic beta-Antagonists/*pharmacology
Antineoplastic Agents, Immunological/*toxicity
Carvedilol/*pharmacology
Myoblasts, Cardiac/*drug effects
Proteome/*metabolism
Trastuzumab/*toxicity
Adrenergic beta-Antagonists/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Cardiomyopathies/prevention & control ; Carvedilol/therapeutic use ; Cell Line ; Cell Survival/drug effects ; Computer Simulation ; Down-Regulation ; Female ; Humans ; Myoblasts, Cardiac/metabolism ; Myoblasts, Cardiac/pathology ; Proteomics ; Receptor, ErbB-2/metabolism ; Trastuzumab/therapeutic use
Czasopismo naukowe
Tytuł :
Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial.
Autorzy :
Kumar M; Department of Hepatology, Institute of Liver and Biliary Sciences, D1 Vasant Kunj, New Delhi, 110070, India. .
Kainth S; Department of Hepatology, Institute of Liver and Biliary Sciences, D1 Vasant Kunj, New Delhi, 110070, India.
Choudhury A; Department of Hepatology, Institute of Liver and Biliary Sciences, D1 Vasant Kunj, New Delhi, 110070, India.
Maiwall R; Department of Hepatology, Institute of Liver and Biliary Sciences, D1 Vasant Kunj, New Delhi, 110070, India.
Mitra LG; Department of Critical Care Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.
Saluja V; Department of Critical Care Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.
Agarwal PM; Department of Critical Care Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.
Shasthry SM; Department of Hepatology, Institute of Liver and Biliary Sciences, D1 Vasant Kunj, New Delhi, 110070, India.
Jindal A; Department of Hepatology, Institute of Liver and Biliary Sciences, D1 Vasant Kunj, New Delhi, 110070, India.
Bhardwaj A; Department of Clinical Research, Institute of Liver and Biliary Sciences, New Delhi, India.
Kumar G; Department of Biostatistics, Institute of Liver and Biliary Sciences, New Delhi, India.
Sarin SK; Department of Hepatology, Institute of Liver and Biliary Sciences, D1 Vasant Kunj, New Delhi, 110070, India.
Pokaż więcej
Źródło :
Hepatology international [Hepatol Int] 2019 Nov; Vol. 13 (6), pp. 800-813. Date of Electronic Publication: 2019 Sep 20.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Acute-On-Chronic Liver Failure/*drug therapy
Adrenergic beta-Antagonists/*therapeutic use
Carvedilol/*therapeutic use
Acute-On-Chronic Liver Failure/complications ; Acute-On-Chronic Liver Failure/mortality ; Administration, Oral ; Adrenergic beta-Antagonists/administration & dosage ; Adult ; Aged ; Carvedilol/administration & dosage ; Disease-Free Survival ; Double-Blind Method ; Drug Administration Schedule ; Esophageal and Gastric Varices/complications ; Female ; Gastrointestinal Hemorrhage/complications ; Humans ; India ; Male ; Middle Aged ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Carvedilol protects against hepatic ischemia/reperfusion injury in high-fructose/high-fat diet-fed mice: Role of G protein-coupled receptor kinase 2 and 5.
Autorzy :
Mohammed SG; Department of Toxic and Narcotic Drugs, Forensic Medicine, Cairo Laboratory, Medicolegal Organization, Ministry of Justice, Cairo, Egypt; Department of Toxic and Narcotic Drugs, Forensic Medicine, Cairo Laboratory, Medicolegal Organization, Ministry of Justice, Cairo, Egypt.
Ibrahim IAAE; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Mahmoud MF; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Mahmoud AAA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt. Electronic address: .
Pokaż więcej
Źródło :
Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2019 Nov 01; Vol. 382, pp. 114750. Date of Electronic Publication: 2019 Sep 10.
Typ publikacji :
Journal Article
MeSH Terms :
Carvedilol/*therapeutic use
Diet, High-Fat/*adverse effects
Fructose/*toxicity
G-Protein-Coupled Receptor Kinase 2/*physiology
G-Protein-Coupled Receptor Kinase 5/*physiology
Reperfusion Injury/*prevention & control
Animals ; Carvedilol/pharmacology ; Fructose/administration & dosage ; G-Protein-Coupled Receptor Kinase 2/antagonists & inhibitors ; G-Protein-Coupled Receptor Kinase 5/antagonists & inhibitors ; Liver Diseases/metabolism ; Liver Diseases/prevention & control ; Male ; Mice ; Protective Agents/pharmacology ; Protective Agents/therapeutic use ; Reperfusion Injury/chemically induced ; Reperfusion Injury/metabolism ; Vasodilator Agents/pharmacology ; Vasodilator Agents/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies